Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study have?
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study has 44 citations in the OpenAlex counts ScholarIQ stores.
When was Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study published?
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study has 2019 year in the ScholarIQ index.
What is the open-access status of Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study?
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study has gold oa status in the ScholarIQ index.
What is the DOI of Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study?
The DOI for Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study is on the source record.
What is the PMID of Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study?
The PMID for Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study is on the source record.
What is the OpenAlex record for Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study?
The OpenAlex for Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study is on the source record.